Emirates Drug Establishment And Korean Ministry Of Food And Drug Safety Sign MoU For Enhanced Pharmaceutical Cooperation

The Emirates Drug Establishment (EDE) has entered into a Memorandum of Understanding (MoU) with the Korean Ministry of Food and Drug Safety. This agreement aims to boost collaboration in pharmaceutical manufacturing and medical products. The MoU, signed in Korea, focuses on sharing expertise in drug regulation, clinical trials, and pharmacovigilance between the UAE and Korea.

The MoU was formalised by Dr. Fatima Mohammed Al Kaabi, Director-General of EDE, and Joon-Su Shin, General Director at the Korean Ministry of Food and Drug Safety. Officials from both countries were present during the signing. The agreement is designed to expedite the registration process for pharmaceutical products that have already been approved by international regulatory bodies like the EU, US, and Japan.

This initiative will help reduce the time needed to introduce new treatments to both nations, benefiting patients with faster access to innovative therapies. Additionally, it aims to improve post-marketing surveillance systems to detect any quality or safety issues with medical products. Early warning mechanisms will be developed to identify counterfeit or defective items swiftly.

The MoU also includes provisions for exchanging clinical and non-clinical research findings between the two parties. This exchange is intended to enhance scientific cooperation in drug development, focusing on innovative biomedical drugs that meet community needs in both countries.

Mutual training programs are part of the agreement to improve personnel efficiency in the pharmaceutical sector. Regular field visits to pharmaceutical facilities in both countries will be organised to share practical experiences. These visits will emphasise implementing Good Clinical Practices (GCP) and Good Manufacturing Practices (GMP).

The agreement also seeks to strengthen research and development cooperation by forming joint task forces. These teams will evaluate biological products and advanced medical equipment while exchanging cutting-edge technologies. Effective strategies for managing innovative medical products like biopharmaceuticals will be developed.

Promoting Innovation and Knowledge Sharing

Joint scientific conferences and workshops will be held to promote knowledge exchange in areas of mutual interest. Dr. Fatima Al Kaabi highlighted that this MoU represents a strategic framework for advancing health cooperation between the two parties. It supports innovation, improves access to modern medicines, and develops effective control systems for medical product safety.

Dr. Al Kaabi stressed that this agreement aligns with EDE's strategy to advance the health sector through international partnerships. This aligns with leadership's vision for fostering cooperation across vital fields. EDE aims for further integration with global counterparts to deliver safe medical products that enhance community well-being.

"The MoU serves as a framework for exchanging research and study results between the two parties," Dr. Al Kaabi added, "as well as for organizing field visits and training programs aimed at enhancing the efficiency of specialised professionals."

With inputs from WAM